OBJECTIVE: To outline the design, baseline data, and 5-year follow-up data of patients with mucopolysaccharidosis (MPS) VI enrolled in the Clinical Surveillance Program (CSP), a voluntary, multinational, observational program. METHODS: The MPS VI CSP was opened in 2005 to collect, for at least 15 years, observational data from standard clinical and laboratory assessments of patients with MPS VI. Baseline and follow-up data are documented by participating physicians in electronic case report forms. RESULTS: Between September 2005 and March 2010 the CSP enrolled 132 patients, including 123 who received enzyme replacement therapy (ERT) with galsulfase. Median age at enrolment was 13 years (range 1-59). Mean baseline data showed impaired growth, hepatosplenomegaly, and reduced endurance and pulmonary function. The most common findings were heart valve disease (90%), reduced visual acuity (79%), impaired hearing (59%), and hepatosplenomegaly (54%). Follow-up data up to 5 years in patients with pre- and post-ERT measurements showed a decrease in urinary glycosaminoglycans and increases in height and weight in patients <16 years and suggested reductions in liver and spleen size and improvements in endurance and pulmonary function after ERT was started. Vision, hearing, and cardiac function were unchanged. Safety data were in line with previous reports. CONCLUSIONS: The CSP represents the largest cross-sectional study of MPS VI to date. This first report provides information on the design and implementation of the program and population statistics for several clinical variables in patients with MPS VI. Data collected over 5 years suggest that ERT provides clinical benefit and is well-tolerated with no new safety concerns.
OBJECTIVE: To outline the design, baseline data, and 5-year follow-up data of patients with mucopolysaccharidosis (MPS) VI enrolled in the Clinical Surveillance Program (CSP), a voluntary, multinational, observational program. METHODS: The MPS VI CSP was opened in 2005 to collect, for at least 15 years, observational data from standard clinical and laboratory assessments of patients with MPS VI. Baseline and follow-up data are documented by participating physicians in electronic case report forms. RESULTS: Between September 2005 and March 2010 the CSP enrolled 132 patients, including 123 who received enzyme replacement therapy (ERT) with galsulfase. Median age at enrolment was 13 years (range 1-59). Mean baseline data showed impaired growth, hepatosplenomegaly, and reduced endurance and pulmonary function. The most common findings were heart valve disease (90%), reduced visual acuity (79%), impaired hearing (59%), and hepatosplenomegaly (54%). Follow-up data up to 5 years in patients with pre- and post-ERT measurements showed a decrease in urinary glycosaminoglycans and increases in height and weight in patients <16 years and suggested reductions in liver and spleen size and improvements in endurance and pulmonary function after ERT was started. Vision, hearing, and cardiac function were unchanged. Safety data were in line with previous reports. CONCLUSIONS: The CSP represents the largest cross-sectional study of MPS VI to date. This first report provides information on the design and implementation of the program and population statistics for several clinical variables in patients with MPS VI. Data collected over 5 years suggest that ERT provides clinical benefit and is well-tolerated with no new safety concerns.
Authors: Sean Turbeville; Helen Nicely; J Douglas Rizzo; Tanya L Pedersen; Paul J Orchard; Mitchell E Horwitz; Edwin M Horwitz; Paul Veys; Carmem Bonfim; Amal Al-Seraihy Journal: Mol Genet Metab Date: 2010-10-25 Impact factor: 4.797
Authors: Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke Journal: Lancet Date: 2009-12-12 Impact factor: 79.321
Authors: Litsa Karageorgos; Doug A Brooks; Anthony Pollard; Elizabeth L Melville; Leanne K Hein; Peter R Clements; David Ketteridge; Stuart J Swiedler; Michael Beck; Roberto Giugliani; Paul Harmatz; James E Wraith; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; John J Hopwood Journal: Hum Mutat Date: 2007-09 Impact factor: 4.878
Authors: Lorne A Clarke; J Edmond Wraith; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Marisa Sidman; Emil D Kakkis; Gerald F Cox Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Roberto Giugliani; Christina Lampe; Nathalie Guffon; David Ketteridge; Elisa Leão-Teles; James E Wraith; Simon A Jones; Cheri Piscia-Nichols; Ping Lin; Adrian Quartel; Paul Harmatz Journal: Am J Med Genet A Date: 2014-04-24 Impact factor: 2.802
Authors: Anke Thümler; Elke Miebach; Christina Lampe; Susanne Pitz; Wolfgang Kamin; Christoph Kampmann; Bianca Link; Eugen Mengel Journal: J Inherit Metab Dis Date: 2012-03-23 Impact factor: 4.982
Authors: José Francisco da Silva Franco; Regina El Dib; Arnav Agarwal; Diogo Soares; Noala Vicensoto Moreira Milhan; Lilian Maria José Albano; Chong Ae Kim Journal: Intractable Rare Dis Res Date: 2017-08
Authors: J de Ruijter; L Ijlst; W Kulik; H van Lenthe; T Wagemans; N van Vlies; F A Wijburg Journal: J Inherit Metab Dis Date: 2012-09-12 Impact factor: 4.982
Authors: Hanna Debiec; Vassili Valayannopoulos; Olivia Boyer; Laure-Hélène Nöel; Patrice Callard; Hélène Sarda; Pascale de Lonlay; Patrick Niaudet; Pierre Ronco Journal: J Am Soc Nephrol Date: 2013-11-21 Impact factor: 10.121